Myriad Genetics, Inc. (NASDAQ: MYGN), a leader in personalized medicine, today announced that it has expanded its companion diagnostic collaboration ...

(Premium-only article. Please sign in or upgrade to SI Premium to view.)

Corporate News Management Comments

Myriad, AstraZeneca and Merck Expand Companion Diagnostic PartnershipApril 4, 2019 7:05 AM